Search - tctmd.com

Displaying 1 - 20 of 47

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2018

November 30, 2018

Certain Risk Factors Carry Higher MI Risk in Women Than in Men

News Daily News

Certain Risk Factors Carry Higher MI Risk in Women Than in Men

November 23, 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

News Conference News AHA 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

November 10, 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

November 05, 2018

Final Phase III Bempedoic Acid Trial Proves Positive for LDL-Lowering

News Daily News

Final Phase III Bempedoic Acid Trial Proves Positive for LDL-Lowering

October 29, 2018

Patients With Schizophrenia Reap Gains From CV Meds After MI

News Daily News

Patients With Schizophrenia Reap Gains From CV Meds After MI

October 24, 2018

Gender Gap May Be Narrowing in ACS Patients, With Mortality Advantage for Elderly Women

News Daily News

Gender Gap May Be Narrowing in ACS Patients, With Mortality Advantage for Elderly Women

October 12, 2018

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

News Daily News

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

October 12, 2018

TCTMD’s Top 10 Most Popular Stories for September 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2018

October 02, 2018

Latest SWEDEHEART Data Show Acute MI Mortality Rates Have Stagnated

News Conference News ESC 2018

Latest SWEDEHEART Data Show Acute MI Mortality Rates Have Stagnated

September 04, 2018

TCTMD’s Top 10 Most Popular Stories for August 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2018

September 04, 2018

ASCEND: Aspirin Doesn’t Look Good for Primary CV Prevention in Diabetic Patients

News Conference News ESC 2018

ASCEND: Aspirin Doesn’t Look Good for Primary CV Prevention in Diabetic Patients

August 26, 2018

CLARIFY: No Survival Benefit With Beta-Blockers Beyond 1 Year Post-MI in Stable CAD

News Conference News ESC 2018

CLARIFY: No Survival Benefit With Beta-Blockers Beyond 1 Year Post-MI in Stable CAD

August 25, 2018

Genetic Risk Score Identifies Individuals at Heightened Risk of CAD and Other Diseases

News Daily News

Genetic Risk Score Identifies Individuals at Heightened Risk of CAD and Other Diseases

Michael O'Riordan

August 16, 2018

Intracranial Hemorrhage Outside of A-fib: Different NOACs, Different Risks

News Daily News

Intracranial Hemorrhage Outside of A-fib: Different NOACs, Different Risks

August 13, 2018

Elevated High-Sensitivity CRP Lingers Long After MI, Observational Study Shows

News Daily News

Elevated High-Sensitivity CRP Lingers Long After MI, Observational Study Shows

Yael L. Maxwell

August 03, 2018

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

News Daily News

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

Michael O'Riordan

August 02, 2018

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

News Daily News

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

Michael O'Riordan

July 31, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.